beta
/M&G Bio: Announcement on using idle own funds for entrusted financial management
NEWS

M&G Bio: Announcement on using idle own funds for entrusted financial management

Shenzhen Stock Exchange
2026/03/31

Securities code: 300138 Securities abbreviation: Chenguang Biotechnology Announcement number: 2026-028

Chenguang Biotechnology Group Co., Ltd.

Announcement on using idle self-owned funds for entrusted financial management

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.

Important content reminder:

  1. Investment types: Financial products with high safety, good liquidity and low risk issued by banks, trusts, securities companies and other financial institutions.

  2. Investment amount: self-owned funds not exceeding RMB 1.3 billion, which can be recycled within the period.

The 22nd meeting of the fifth board of directors of Chenguang Biotechnology Group Co., Ltd. (hereinafter referred to as the "Company") reviewed and approved the "Proposal on the Use of Idle Own Funds for Entrusted Financial Management", and agreed that the company will use its temporarily idle own funds of no more than RMB 1.3 billion to purchase financial products with high safety, good liquidity and low risk in stages, and the period will not exceed 12 from the date of the board of directors' resolution, taking into account the periodic idleness of funds, expected peaks, etc., without affecting the daily business development. months, and the quota can be used on a recurring basis within the period.

1. The use of idle self-owned funds for entrusted financial management this time

  1. Planned investment methods and purposes

The planned investments are financial products with high safety, good liquidity and low risk issued by banks, trusts, securities companies and other financial institutions. They are not used for other securities investments, and financial products with stocks and their derivatives and unsecured bonds as investment targets are not purchased. There is no related relationship between the company and the trustees of entrusted financial management.

Without affecting the company's normal business operations, using its own funds for entrusted financial management can improve the efficiency of fund use, increase cash asset returns, and create better returns for the company and shareholders.

  1. Planned investment amount and period

The company plans to use no more than 1.3 billion yuan of its own funds for entrusted financial management.

The term shall not exceed 12 months from the date of this board of directors resolution. The quota within the period shall be recycled and the amount at any time within the period shall not exceed the investment quota.

  1. Source of funds

The company has idle own funds and does not involve raised funds or bank credit funds.

  1. Others

Within the quota range and validity period, the legal representative of the company is authorized to sign relevant documents, and the Finance Department is responsible for the specific implementation, accounting and other work.

2. Investment risk warning and risk control measures

The company's use of its own funds for entrusted financial management is limited to financial products with high security, good liquidity and low risk. Within the quota approved by the board of directors, timely and appropriate investments are made based on changes in the economic situation and financial markets. However, the financial market is affected by the macro economy and the risk of the investment being affected by financial market fluctuations cannot be ruled out. The company plans to take the following measures:

  1. The company has formulated the "Entrusted Financial Management Management System", which provides detailed regulations on the authority, review process, daily monitoring and verification of entrusted financial management. The company will conduct entrusted financial management in accordance with relevant systems, and implement inspection and supervision to strictly control risks and ensure the safety of financial management funds.

  2. The company will strictly abide by the principle of prudent investment and select products with high safety, good liquidity and low risk for investment; timely analyze and track the investment direction and progress of the products. Once it is discovered or judged that there are risk factors that may affect the safety of the company's funds, it will promptly take corresponding measures to control investment risks and report any abnormal situations in a timely manner so that effective measures can be taken immediately to recover funds and avoid or reduce the company's losses.

  3. The company's financial department arranges for dedicated personnel to establish ledgers to manage the purchased products, establish and improve accounting accounts, and do a good job in accounting for the use of funds.

  4. The company’s internal audit department will supervise and inspect financial product projects.

  5. The Audit Committee will supervise and inspect the use of funds, and may hire a professional agency to conduct an audit if necessary.

  6. The company will strictly comply with relevant regulatory regulations and perform its information disclosure obligations in a timely manner.

3. Impact on the company

Without affecting the company's normal business operations, using its own funds for entrusted financial management can improve the efficiency of fund use, increase cash asset returns, and create better returns for the company and shareholders.

The company will conduct corresponding accounting treatment for its own funds cash management business in accordance with relevant regulations such as "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments" and "Accounting Standards for Business Enterprises No. 37 - Presentation of Financial Instruments", which will be reflected in the relevant accounts of the balance sheet and profit and loss statement.

4. Implementation decision-making process

The 22nd meeting of the fifth board of directors held on March 29, 2026 reviewed and approved the "Proposal on Using Idle Own Funds for Entrusted Financial Management".

5. Documents for reference

Resolution of the 22nd meeting of the company’s fifth board of directors

Announcement hereby

Board of Directors of Chenguang Biotechnology Group Co., Ltd.

March 31, 2026